Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 519

1.

Neuroimaging for Migraine: The American Headache Society Systematic Review and Evidence-Based Guideline.

Evans RW, Burch RC, Frishberg BM, Marmura MJ, Mechtler LL, Silberstein SD, Turner DP.

Headache. 2019 Dec 31. doi: 10.1111/head.13720. [Epub ahead of print]

PMID:
31891197
2.

Correction to: Galcanezumab in episodic migraine: subgroup analyses of efficacy by high versus low frequency of migraine headaches in phase 3 studies (EVOLVE-1 & EVOLVE-2).

Silberstein SD, Stauffer VL, Day KA, Lipsius S, Wilson MC.

J Headache Pain. 2019 Dec 27;20(1):118. doi: 10.1186/s10194-019-1069-x.

3.

The Influence of Migraine on Driving: Current Understanding, Future Directions, and Potential Implications of Findings.

Tepper SJ, Silberstein SD, Rosen NL, Lipton RB, Dennehy EB, Dowsett SA, Doty E.

Headache. 2020 Jan;60(1):178-189. doi: 10.1111/head.13716. Epub 2019 Dec 2.

PMID:
31792964
4.

Dihydroergotamine (DHE) - Then and Now: A Narrative Review.

Silberstein SD, Shrewsbury SB, Hoekman J.

Headache. 2020 Jan;60(1):40-57. doi: 10.1111/head.13700. Epub 2019 Nov 17. Review.

PMID:
31737909
5.

Long-term tolerability and nonvascular safety of erenumab, a novel calcitonin gene-related peptide receptor antagonist for prevention of migraine: A pooled analysis of four placebo-controlled trials with long-term extensions.

Ashina M, Kudrow D, Reuter U, Dolezil D, Silberstein S, Tepper SJ, Xue F, Picard H, Zhang F, Wang A, Zhou Y, Hong F, Klatt J, Mikol DD.

Cephalalgia. 2019 Dec;39(14):1798-1808. doi: 10.1177/0333102419888222. Epub 2019 Nov 10.

PMID:
31707815
6.

Preventive Treatment for Episodic Migraine.

Parikh SK, Silberstein SD.

Neurol Clin. 2019 Nov;37(4):753-770. doi: 10.1016/j.ncl.2019.07.004. Epub 2019 Aug 22. Review.

PMID:
31563231
7.

Novel Medications for the Treatment of Migraine.

Ceriani CEJ, Wilhour DA, Silberstein SD.

Headache. 2019 Oct;59(9):1597-1608. doi: 10.1111/head.13661. Epub 2019 Sep 26. Review.

PMID:
31559638
8.

FORWARD Study: Evaluating the Comparative Effectiveness of OnabotulinumtoxinA and Topiramate for Headache Prevention in Adults With Chronic Migraine.

Rothrock JF, Adams AM, Lipton RB, Silberstein SD, Jo E, Zhao X, Blumenfeld AM; FORWARD Study investigative group.

Headache. 2019 Nov;59(10):1700-1713. doi: 10.1111/head.13653. Epub 2019 Sep 26.

9.

Targeting CGRP for the Prevention of Migraine and Cluster Headache: A Narrative Review.

Yuan H, Spare NM, Silberstein SD.

Headache. 2019 Jul;59 Suppl 2:20-32. doi: 10.1111/head.13583. Review.

PMID:
31291020
10.

Galcanezumab in episodic migraine: subgroup analyses of efficacy by high versus low frequency of migraine headaches in phase 3 studies (EVOLVE-1 & EVOLVE-2).

Silberstein SD, Stauffer VL, Day KA, Lipsius S, Wilson MC.

J Headache Pain. 2019 Jun 28;20(1):75. doi: 10.1186/s10194-019-1024-x. Erratum in: J Headache Pain. 2019 Dec 27;20(1):118.

11.

Differential efficacy of non-invasive vagus nerve stimulation for the acute treatment of episodic and chronic cluster headache: A meta-analysis.

de Coo IF, Marin JC, Silberstein SD, Friedman DI, Gaul C, McClure CK, Tyagi A, Liebler E, Tepper SJ, Ferrari MD, Goadsby PJ.

Cephalalgia. 2019 Jul;39(8):967-977. doi: 10.1177/0333102419856607. Epub 2019 Jun 10.

12.

Eptinezumab for prevention of chronic migraine: A randomized phase 2b clinical trial.

Dodick DW, Lipton RB, Silberstein S, Goadsby PJ, Biondi D, Hirman J, Cady R, Smith J.

Cephalalgia. 2019 Aug;39(9):1075-1085. doi: 10.1177/0333102419858355. Epub 2019 Jun 24.

PMID:
31234642
13.

Fremanezumab for the preventive treatment of migraine.

Silberstein SD, Cohen JM, Yeung PP.

Expert Opin Biol Ther. 2019 Aug;19(8):763-771. doi: 10.1080/14712598.2019.1627323. Epub 2019 Jul 1.

PMID:
31177856
14.

Pathophysiology, prevention, and treatment of medication overuse headache.

Diener HC, Dodick D, Evers S, Holle D, Jensen RH, Lipton RB, Porreca F, Silberstein S, Schwedt T.

Lancet Neurol. 2019 Sep;18(9):891-902. doi: 10.1016/S1474-4422(19)30146-2. Epub 2019 Jun 4. Review.

PMID:
31174999
15.

Long-term safety and tolerability of erenumab: Three-plus year results from a five-year open-label extension study in episodic migraine.

Ashina M, Goadsby PJ, Reuter U, Silberstein S, Dodick D, Rippon GA, Klatt J, Xue F, Chia V, Zhang F, Cheng S, Mikol DD.

Cephalalgia. 2019 Oct;39(11):1455-1464. doi: 10.1177/0333102419854082. Epub 2019 May 30.

16.

Early onset of effect of onabotulinumtoxinA for chronic migraine treatment: Analysis of PREEMPT data.

Dodick DW, Silberstein SD, Lipton RB, DeGryse RE, Adams AM, Diener HC.

Cephalalgia. 2019 Jul;39(8):945-956. doi: 10.1177/0333102418825382. Epub 2019 May 21.

PMID:
31112399
17.

Vestibular Neuroscience for the Headache Specialist.

Balaban CD, Black RD, Silberstein SD.

Headache. 2019 Jul;59(7):1109-1127. doi: 10.1111/head.13550. Epub 2019 May 11.

PMID:
31077365
18.

Remote Electrical Neuromodulation (REN) Relieves Acute Migraine: A Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial.

Yarnitsky D, Dodick DW, Grosberg BM, Burstein R, Ironi A, Harris D, Lin T, Silberstein SD.

Headache. 2019 Sep;59(8):1240-1252. doi: 10.1111/head.13551. Epub 2019 May 9.

19.

Adherence to the 2008 IHS guidelines for controlled trials of drugs for the preventive treatment of chronic migraine in adults.

Deen M, Martinelli D, Pijpers J, Diener HC, Silberstein S, Ferrari MD, Ashina M, Tassorelli C, Yuan H.

Cephalalgia. 2019 Jul;39(8):1058-1066. doi: 10.1177/0333102419847751. Epub 2019 May 1.

PMID:
31042062
20.

Erenumab in chronic migraine: Patient-reported outcomes in a randomized double-blind study.

Lipton RB, Tepper SJ, Reuter U, Silberstein S, Stewart WF, Nilsen J, Leonardi DK, Desai P, Cheng S, Mikol DD, Lenz R.

Neurology. 2019 May 7;92(19):e2250-e2260. doi: 10.1212/WNL.0000000000007452. Epub 2019 Apr 17.

21.

Safety and Tolerability of Fremanezumab for the Prevention of Migraine: A Pooled Analysis of Phases 2b and 3 Clinical Trials.

Silberstein SD, McAllister P, Ning X, Faulhaber N, Lang N, Yeung P, Schiemann J, Aycardi E, Cohen JM, Janka L, Yang R.

Headache. 2019 Jun;59(6):880-890. doi: 10.1111/head.13534. Epub 2019 Apr 12.

PMID:
30977520
22.

The endocannabinoid system in migraine: from bench to pharmacy and back.

Tassorelli C, Greco R, Silberstein SD.

Curr Opin Neurol. 2019 Jun;32(3):405-412. doi: 10.1097/WCO.0000000000000688.

PMID:
30883435
23.

Current Status of Antiepileptic Drugs as Preventive Migraine Therapy.

Parikh SK, Silberstein SD.

Curr Treat Options Neurol. 2019 Mar 18;21(4):16. doi: 10.1007/s11940-019-0558-1. Review.

PMID:
30880369
24.

Invited Commentary on Preventive Anti-Migraine Therapy (PAMT).

Jain S, Silberstein SD.

Curr Treat Options Neurol. 2019 Mar 14;21(4):14. doi: 10.1007/s11940-019-0555-4. Review.

PMID:
30868470
25.

Development of a claims-based algorithm to identify potentially undiagnosed chronic migraine patients.

Pavlovic JM, Yu JS, Silberstein SD, Reed ML, Kawahara SH, Cowan RP, Dabbous F, Campbell KL, Shewale AR, Pulicharam R, Kowalski JW, Viswanathan HN, Lipton RB.

Cephalalgia. 2019 Apr;39(4):465-476. doi: 10.1177/0333102418825373. Epub 2019 Mar 9.

26.

Guidelines of the International Headache Society for controlled trials of acute treatment of migraine attacks in adults: Fourth edition.

Diener HC, Tassorelli C, Dodick DW, Silberstein SD, Lipton RB, Ashina M, Becker WJ, Ferrari MD, Goadsby PJ, Pozo-Rosich P, Wang SJ, Mandrekar J; International Headache Society Clinical Trials Standing Committee.

Cephalalgia. 2019 May;39(6):687-710. doi: 10.1177/0333102419828967. Epub 2019 Feb 26.

27.

Migraine Headache: Diagnosis and Current and Emerging Preventive Treatments.

Lipton RB, Silberstein S.

Prim Care Companion CNS Disord. 2018 Dec 27;20 suppl E1. pii: li17059su1c. doi: 10.4088/PCC.li17059su1c.

PMID:
30698925
28.

Calcitonin Gene-Related Peptide Antagonists in the Treatment of Episodic Migraine.

Yuan H, White CS, Silberstein SD.

Clin Pharmacol Ther. 2019 May;105(5):1121-1129. doi: 10.1002/cpt.1356. Epub 2019 Mar 18.

PMID:
30648737
29.

Assessing real-time signaling and agonist-induced CRHR1 internalization by optical methods.

Dos Santos Claro PA, Inda C, Armando NG, Piazza VG, Attorresi A, Silberstein S.

Methods Cell Biol. 2019;149:239-257. doi: 10.1016/bs.mcb.2018.08.009. Epub 2018 Sep 17.

PMID:
30616823
30.

The Effect of Beginning Treatment With Fremanezumab on Headache and Associated Symptoms in the Randomized Phase 2 Study of High Frequency Episodic Migraine: Post-Hoc Analyses on the First 3 Weeks of Treatment.

Silberstein SD, Rapoport AM, Loupe PS, Aycardi E, McDonald M, Yang R, Bigal ME.

Headache. 2019 Mar;59(3):383-393. doi: 10.1111/head.13446. Epub 2018 Nov 18.

PMID:
30450545
31.

Lasmiditan is an effective acute treatment for migraine: A phase 3 randomized study.

Kuca B, Silberstein SD, Wietecha L, Berg PH, Dozier G, Lipton RB; COL MIG-301 Study Group.

Neurology. 2018 Dec 11;91(24):e2222-e2232. doi: 10.1212/WNL.0000000000006641. Epub 2018 Nov 16.

32.

A fluorescence nanoscopy marker for corticotropin-releasing hormone type 1 receptor: computer design, synthesis, signaling effects, super-resolved fluorescence imaging, and in situ affinity constant in cells.

Szalai AM, Armando NG, Barabas FM, Stefani FD, Giordano L, Bari SE, Cavasotto CN, Silberstein S, Aramendía PF.

Phys Chem Chem Phys. 2018 Nov 28;20(46):29212-29220. doi: 10.1039/c8cp06196c.

PMID:
30427333
33.

Basic Considerations for the Use of Monoclonal Antibodies in Migraine.

Levin M, Silberstein SD, Gilbert R, Lucas S, Munsie L, Garrelts A, Kennedy K, Everman N, Pearlman E.

Headache. 2018 Nov;58(10):1689-1696. doi: 10.1111/head.13439. Epub 2018 Nov 13. Review.

34.

Health care Resource Utilization and Migraine Disability Along the Migraine Continuum Among Patients Treated for Migraine.

Silberstein SD, Lee L, Gandhi K, Fitzgerald T, Bell J, Cohen JM.

Headache. 2018 Nov;58(10):1579-1592. doi: 10.1111/head.13421. Epub 2018 Oct 30.

PMID:
30375650
35.

From LBR-101 to Fremanezumab for Migraine.

Bigal ME, Rapoport AM, Silberstein SD, Walter S, Hargreaves RJ, Aycardi E.

CNS Drugs. 2018 Nov;32(11):1025-1037. doi: 10.1007/s40263-018-0579-4. Review.

PMID:
30311143
36.

Erenumab in the treatment of migraine.

Jain S, Yuan H, Spare N, Silberstein SD.

Pain Manag. 2018 Nov 1;8(6):415-426. doi: 10.2217/pmt-2018-0037. Epub 2018 Sep 21. Review.

PMID:
30235976
37.

Rationale for electrical parameter determination in external trigeminal nerve stimulation (eTNS) for migraine: A narrative review.

Lauritsen CG, Silberstein SD.

Cephalalgia. 2019 May;39(6):750-760. doi: 10.1177/0333102418796781. Epub 2018 Aug 23.

PMID:
30139273
38.

Ketamine for Refractory Headache: A Retrospective Analysis.

Schwenk ES, Dayan AC, Rangavajjula A, Torjman MC, Hernandez MG, Lauritsen CG, Silberstein SD, Young W, Viscusi ER.

Reg Anesth Pain Med. 2018 Nov;43(8):875-879. doi: 10.1097/AAP.0000000000000827.

PMID:
29923953
39.

Effect of Fremanezumab Compared With Placebo for Prevention of Episodic Migraine: A Randomized Clinical Trial.

Dodick DW, Silberstein SD, Bigal ME, Yeung PP, Goadsby PJ, Blankenbiller T, Grozinski-Wolff M, Yang R, Ma Y, Aycardi E.

JAMA. 2018 May 15;319(19):1999-2008. doi: 10.1001/jama.2018.4853.

40.

Correction to: OnabotulinumtoxinA: A Review in the Prevention of Chronic Migraine.

Frampton JE, Silberstein S.

Drugs. 2018 Apr;78(6):715. doi: 10.1007/s40265-018-0906-6.

41.

The Use and Method of Action of Intravenous Lidocaine and Its Metabolite in Headache Disorders.

Berk T, Silberstein SD.

Headache. 2018 May;58(5):783-789. doi: 10.1111/head.13298. Epub 2018 Mar 14. Review.

PMID:
29536530
42.

OnabotulinumtoxinA: A Review in the Prevention of Chronic Migraine.

Frampton JE, Silberstein S.

Drugs. 2018 Apr;78(5):589-600. doi: 10.1007/s40265-018-0894-6. Review. Erratum in: Drugs. 2018 Apr 20;:.

43.

A multicenter, prospective, single arm, open label, observational study of sTMS for migraine prevention (ESPOUSE Study).

Starling AJ, Tepper SJ, Marmura MJ, Shamim EA, Robbins MS, Hindiyeh N, Charles AC, Goadsby PJ, Lipton RB, Silberstein SD, Gelfand AA, Chiacchierini RP, Dodick DW.

Cephalalgia. 2018 May;38(6):1038-1048. doi: 10.1177/0333102418762525. Epub 2018 Mar 4.

44.

Guidelines of the International Headache Society for controlled trials of preventive treatment of chronic migraine in adults.

Tassorelli C, Diener HC, Dodick DW, Silberstein SD, Lipton RB, Ashina M, Becker WJ, Ferrari MD, Goadsby PJ, Pozo-Rosich P, Wang SJ; International Headache Society Clinical Trials Standing Committee.

Cephalalgia. 2018 Apr;38(5):815-832. doi: 10.1177/0333102418758283. Epub 2018 Mar 4.

PMID:
29504482
45.

Preventive Therapies for Chronic Migraine.

Silberstein SD, Yeung PP, Aycardi E.

N Engl J Med. 2018 Feb 22;378(8):774. doi: 10.1056/NEJMc1716990. No abstract available.

PMID:
29466162
46.

Current management: migraine headache.

Silberstein SD.

CNS Spectr. 2017 Dec;22(S1):1-13. doi: 10.1017/S1092852917000864. Review.

PMID:
29350125
47.

Percutaneous Closure of Patent Foramen Ovale in Patients With Migraine: The PREMIUM Trial.

Tobis JM, Charles A, Silberstein SD, Sorensen S, Maini B, Horwitz PA, Gurley JC.

J Am Coll Cardiol. 2017 Dec 5;70(22):2766-2774. doi: 10.1016/j.jacc.2017.09.1105.

48.

Fremanezumab for the Preventive Treatment of Chronic Migraine.

Silberstein SD, Dodick DW, Bigal ME, Yeung PP, Goadsby PJ, Blankenbiller T, Grozinski-Wolff M, Yang R, Ma Y, Aycardi E.

N Engl J Med. 2017 Nov 30;377(22):2113-2122. doi: 10.1056/NEJMoa1709038.

49.

The emerging role of gammaCore® in the management of cluster headache: expert panel recommendations.

Silberstein SD, Calhoun AH, Treppendahl C, Dodick DW, Rapoport AM, Mamidi A, Vargas P, Ebert TH, Tepper SJ.

Am J Manag Care. 2017 Nov;23(17 Suppl):S326-S333.

50.

CGRP Monoclonal Antibodies for Migraine: Rationale and Progress.

Yuan H, Lauritsen CG, Kaiser EA, Silberstein SD.

BioDrugs. 2017 Dec;31(6):487-501. doi: 10.1007/s40259-017-0250-5. Review.

PMID:
29116598

Supplemental Content

Loading ...
Support Center